451-02-017 / 451-02-017 ISMRM Abstract

Advancing contrast enhanced MRI – The potential of the new contrast agent Gadoquatrane

Primary: Contrast Mechanisms - Contrast Agents

Secondary: Physics & Engineering - Safety

451-02-017 · Advances in Contrast Mechanisms · Tuesday, 12 May, 1:40 PM–3:16 PM · Power Pitch Theatre 1

Keywords: Contrast Mechanisms Safety MRI Sustainability T1 relaxation time Contrast enhanced MRI

Accepted

Hubertus Pietsch ¹, Stephan Gruendemann, Jessica Lohrke, Janina Boyken, Gregor Jost²

¹Bayer AG, Berlin, Germany

²Radiology, Bayer AG, Berlin, Germany

Presenting Author: Hubertus Pietsch

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. [1] Lohrke J, Berger M, Frenzel T, et al. Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent. Invest Radiol. 2022;57(10):629-638

2. [2] Frenzel T, Wels T, Pietsch H, et al. Recent developments and future perspectives in magnetic resonance imaging and computed tomography contrast media. Invest Radiol. 2025; doi: 10.1097 Online ahead of print

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/451-02-017